- THIAZOLIDINONE COMPOUNDS AND USE THEREOF
-
A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.
- -
-
Paragraph 0257-0258
(2017/09/21)
-
- 2-PHENYL BENZOYLAMIDES
-
Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein.
- -
-
Page/Page column 68
(2011/12/04)
-
- PYRIMIDINE DERIVATIVE
-
A compound represented by the general formula (1) which has an inhibitory effect on PDE4 activity and produces little adverse side effects: wherein Ar1 represents a furyl, thienyl, triazolyl, thiazolyl, oxazolyl or benzothiazolyl group; Ar2 represents -E-AR21-G-Q (where Ar21 represents a benzene or naphthalene ring; E represents a single bond or an alkylene group; G represents a single bond, an alkylene group or an alkenylene group; and Q represents a carboxyl group, -CON(R41)(R42) or -COOR43), -E-Ar21-G2-G-Q (where E, Ar21, G and Q are as defined above; and G2 represents -O-, -S-, -SO-, -SO2- or -NRG21-) or a monocyclic aromatic heterocyclic ring other than a pyrazolyl group; R1 and R2 are the same as or different from each other and independently represent a hydrogen atom, an alkyl group which may be substituted or the like; and R3 represents a hydrogen atom or an alkyl group which may be substituted.
- -
-
Page/Page column 173
(2010/11/25)
-
- ESTER COMPOUND AND MEDICINAL USE THEREOF
-
A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein ???R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; ???X is -COO- or -CON(R10)-; ???R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.; ???ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; ???Alk1 and Alk2 are each independently alkanediyl, etc.; ???l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
- -
-
-
- Partial dopamine receptor agonists with different degrees of intrinsic activity within a series of 2-(4-aminophenyl)-N,N-dipropylethylamine derivatives: Synthetic chemistry and structure-activity relationships
-
A series of 2-(4-aminophenyl)-N,N-dipropylethylamine derivatives were synthesized and tested for in vivo intrinsic activity at brain dopamine receptors in the rat. Differences in the sensitivity of dopamine receptors pre- and post-synaptically in the reserpine-treated rat were used to estimate the intrinsic activity of the various compounds as dopamine receptor agonists. Thus, the ability of the compounds to antagonize reserpine-induced increase in neostriatal dopamine synthesis and the suppression of spontaneous locomotor activity were taken as pre- and post-synaptic indices, respectively. The compounds in the present series display a gradient of intrinsic activity depending on the substituents in the aromatic ring. The presence of an amino group or an appropriate acylamino group in the 4-position was found to be critical for the biological activity of these compounds as agonists or antagonists. The introduction of halogen or a trifluoromethyl group in the 3-position resulted in high intrinsic activity (ie, agonist activity). The incorporation of a methyl group in the 3-position or halogens in the 3,5-positions resulted in a gradual decrease in intrinsic activity at rat brain dopamine receptors resulting in a series of compounds ranging from a full agonist to dopamine receptor blockade.
- Florvall,Hillegaart,Malmberg,Wijkstroem,Ahlenius
-
p. 133 - 142
(2007/10/03)
-
- Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides
-
A number of tricyclic carboxamides have been synthesized and tested to evaluate their ability to reverse multidrug resistance in the CHRC/5 cell line.Among them the acridone derivatives were the most potent.A key feature is the presence of a dimethoxybenzyl or phenethylamine cationic site, separated from the tricyclic lipophilic part by a carbamoylphenyl chain.Optimization led to compounds 2 orders of magnitude more active than the prototype inhibitors verapamil and amiodarone.On the basis of in vitro and in vivo activities, 9,10-dihydro-5-methoxy-9-oxo-N-phenyl>-4-acridinecarboxamide (84) has been selected for further development.
- Dodic, Nerina,Dumaitre, Bernard,Daugan, Alain,Pianetti, Pascal
-
p. 2418 - 2426
(2007/10/02)
-
